SOUTH SAN FRANCISCO, Calif., June 1, 2026
IDEAYA Biosciences and Servier have unveiled compelling results from the registrational Phase 2/3 OptimUM-02 trial, demonstrating that the combination of darovasertib and crizotinib significantly improves outcomes in patients with first-line HLA-A*02:01 negative metastatic uveal melanoma (mUM). Presented in a late-breaking oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, the findings position the investigational combination as a potential new standard of care for a patient population with no currently approved treatment options. The study achieved its primary endpoint, delivering a statistically significant and clinically meaningful improvement in progression-free survival (PFS) while also showing substantial gains in objective response rates and disease control. The positive results further strengthen the growing role of precision oncology strategies in addressing rare and aggressive cancers with high unmet medical need.
Darovasertib Combination Delivers Significant Progression-Free Survival Benefit
The global OptimUM-02 trial enrolled 313 patients with first-line HLA-A*02:01 negative metastatic uveal melanoma and randomized participants to receive either the darovasertib-crizotinib combination or investigator’s choice of therapy, which largely consisted of immune checkpoint inhibitor regimens. The trial successfully met its primary endpoint, with patients receiving the darovasertib combination achieving a median progression-free survival of 6.9 months, compared with 3.1 months in the control arm.
This translated into a remarkable 58% reduction in the risk of disease progression, representing one of the most significant clinical advances reported to date in metastatic uveal melanoma. Investigator-assessed outcomes further reinforced these findings, demonstrating a median PFS of 6.7 months versus 2.7 months for standard therapies. Importantly, the treatment benefit was consistently observed across multiple patient subgroups, including differences in age, gender, metastatic site, disease burden, and prior treatment characteristics, underscoring the broad applicability of the therapeutic approach.
Robust Response Rates Highlight Potential New Standard of Care
Advertisement
Beyond progression-free survival, the darovasertib combination demonstrated substantial improvements across several key secondary endpoints. Patients treated with the combination achieved an objective response rate (ORR) of 37.1%, compared with only 5.8% among patients receiving investigator-selected therapies. Similarly, the disease control rate (DCR) reached 73.3%, more than doubling the 31.1% observed in the control arm. These improvements suggest that the therapy not only delays disease progression but also produces meaningful tumor shrinkage and prolonged disease stabilization in a significant proportion of patients.
Metastatic uveal melanoma remains one of the most challenging ocular cancers to treat, particularly among patients who are HLA-A*02:01 negative and therefore ineligible for currently approved targeted therapies. The robust efficacy profile observed in OptimUM-02 indicates that darovasertib and crizotinib may offer a transformative new treatment option for this underserved patient population.
Favorable Safety Profile Supports Regulatory Advancement
Equally important, the investigational regimen demonstrated a generally manageable safety profile consistent with previous studies. Treatment-related serious adverse events occurred in 9.2% of patients receiving the combination compared with 25.0% in the control group. Discontinuation rates due to treatment-related adverse events remained notably low, at 2.5% for darovasertib and 10.0% for crizotinib, compared with 19.0% among patients receiving standard therapies. Common Grade 3 and Grade 4 treatment-related adverse events included diarrhea, syncope, and hypotension, while overall tolerability remained favorable.
Overall survival data remain immature; however, investigators reported an encouraging early trend favoring the darovasertib combination, with additional analyses expected during future pre-specified interim evaluations. Building on these results, IDEAYA has already initiated the regulatory submission process under the FDA’s Real-Time Oncology Review (RTOR) program and expects to complete its New Drug Application filing during the second half of 2026. If approved, the combination could become one of the first precision medicine therapies specifically developed for HLA-A*02:01 negative metastatic uveal melanoma, potentially reshaping treatment standards and improving outcomes for patients facing this aggressive disease.
Source: IDEAYA Biosciences, Servier press release
